

Claims

1. Use of a kit including:

- i) a first container comprising at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-L1);
- ii) a second container comprising at least one dose of a medicament comprising a VEGFR inhibitor; and
- iii) a package insert comprising instructions to treat a subject for cancer using the medicaments;

in the manufacture of a medicament for the treatment of cancer in a subject, wherein the PD-L1 antagonist is an anti-PD-L1 monoclonal antibody comprising three CDRs from a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 8 and three CDRs from a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 9, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-inda-zol-6-ylsulfanyl]benzamide or a pharmaceutically acceptable salt thereof, and wherein the subject is a human.